THE COLUMN GROUP LLC

The Column Group will stay committed through the life cycle of each of its 5 to 8 companies, and manage risk in each company’s pipeline rather than through a large portfolio of companies. TCG will evaluate the enormous opportunities in the areas of cancer, inflammation, infectious disease, metabolic disorders, cardiovascular disease and nervous system disorders. The TCG team includes some of today’s most prominent experts in these medical fields. TCG’s substantial financial commitment will enable its portfolio companies to build sustainable pipelines of new drugs, creating value as stand-alone companies or as attractive acquisition targets for large pharma companies.